Literature DB >> 31118243

Efgartigimod: A novel antibody depletion therapy in myasthenia gravis.

Amanda C Guidon1, Vern C Juel2.   

Abstract

Entities:  

Year:  2019        PMID: 31118243     DOI: 10.1212/WNL.0000000000007605

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  2 in total

Review 1.  Novel Treatments in Myasthenia Gravis.

Authors:  Deepak Menon; Carolina Barnett; Vera Bril
Journal:  Front Neurol       Date:  2020-06-30       Impact factor: 4.003

Review 2.  New Approaches to Targeting B Cells for Myasthenia Gravis Therapy.

Authors:  Ruksana Huda
Journal:  Front Immunol       Date:  2020-02-21       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.